Rob is a partner in our corporate practice and has a particular focus on venture capital work, acting for high growth technology companies and institutional investors on refinancing transactions and company exits. Rob also works with clients in the private equity sector, where he has experience of acting on buyouts, buy-and-build consolidator projects and related exits.
Many of Rob's clients operate in the life sciences and tech, media and communications sectors, where the technology has been developed at some of the world's leading research institutions based in the UK. Rob has worked on the legal drafting committee for the BVCA's early stage model documents. He co-leads OC Ventures, the firm's dedicated resource centre for the ventures ecosystem.
Rob is head of Osborne Clarke's Thames Valley office.
"Rob Hayes – one of the very best in VC. Always approachable and a delight to work with. Technically outstanding combined with an incredible commercial approach is a winning combination."
Oxular Limited
Advised Oxular Limited on its £27 million fundraise led by Forbion Partners.
Nexeon Limited
Advised Nexeon on its USD200 million investment from a consortium of investors led by SKC Chemicals.
Shareholders of Lumenisity Limited
Advised management, Parkwalk, BGF, Heraeus & Riverview on the sale of the company to Microsoft Corporation.
Insights
UK general election: what are the potential implications for the life sciences and healthcare sector?
Starting up, scaling up and the investment and exit process from high growth businesses in the UK – in practice
Venture capital deal terms trends in the UK
The government has vision for the UK as the world's leading hub for life sciences
Details on the funding of the 10-year strategy, which builds on the UK's world-class capability and on lessons from the...